Barinthus Biotherapeutics
BRNS
13 hedge funds and large institutions have $23.2M invested in Barinthus Biotherapeutics in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
26% more capital invested
Capital invested by funds: $18.4M → $23.2M (+$4.78M)
8% more funds holding
Funds holding: 12 → 13 (+1)
3.65% more ownership
Funds ownership: 13.28% → 16.93% (+3.6%)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HH
HSG Holding
Na,
Hong Kong
|
+$6.84M |
| 2 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$1.29M |
| 3 |
Morgan Stanley
New York
|
+$21.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IIM
Ipswich Investment Management
Beverly,
Massachusetts
|
-$59.7K |
| 2 |
Millennium Management
New York
|
-$35K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$7.2K |
| 4 |
JP Morgan Chase
New York
|
-$53 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AI
1
Alphabet Inc
Mountain View,
California
| $6.74M | – | – | – |
|
|
HH
2
HSG Holding
Na,
Hong Kong
| $6.32M | +$6.84M | +1,420,473 | New |
|
|
DF
3
DC Funds
Mclean,
Virginia
| $2.86M | – | – | – |
|
|
LIP
4
Liontrust Investment Partners
London,
United Kingdom
| $2.67M | – | – | – |
|
|
BCM
5
BlueCrest Capital Management
St Helier,
Jersey
| $2.42M | – | – | – |
|
|
6
Tudor Investment Corp
Stamford,
Connecticut
| $1.19M | +$1.29M | +266,927 | New |
|
|
JHU
7
Johns Hopkins University
Baltimore,
Maryland
| $480K | – | – | – |
|
|
8
Millennium Management
New York
| $273K | -$35K | -7,261 | -11% |
|
|
IIM
9
Ipswich Investment Management
Beverly,
Massachusetts
| $178K | -$59.7K | -12,400 | -24% |
|
|
10
Morgan Stanley
New York
| $61K | +$21.7K | +4,511 | +49% |
|
|
MGIM
11
M&G Investment Management
London,
United Kingdom
| $4.35K | – | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| $2K | -$7.2K | -1,494 | -76% |
|
|
13
JP Morgan Chase
New York
| – | -$53 | -11 | -65% |
|
BRNS Hedge Fund Activity: Q2 2022 in Review
13 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q2 2022, worth a combined $23.2M — up 26% from $18.4M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BRNS positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 4 trimmed.
The largest buyer was HSG Holding, opening a new position worth an estimated $6.84M. The largest seller was Ipswich Investment Management, cutting an estimated $59.7K.
- 13 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q2 2022, up from 12 in Q1 2022.
- Funds reported $23.2M of Barinthus Biotherapeutics stock for Q2 2022, up 26% quarter-over-quarter.
- 2 funds opened new Barinthus Biotherapeutics positions in Q2 2022 and 1 closed out, a net change of +1 holder.
- The largest Barinthus Biotherapeutics buyer in Q2 2022 was HSG Holding, an estimated $6.84M added.
- The largest Barinthus Biotherapeutics seller in Q2 2022 was Ipswich Investment Management, an estimated $59.7K sold.
Based on aggregated 13F filings for Q2 2022.